Rapport Therapeutics’ RAP-219 Delivers Positive Efficacy Signal in Bipolar Mania, but Agitation and Dropouts Cap Near-Term Upside
Rapport’s RAP-219 hit key YMRS endpoints in bipolar mania, but agitation imbalance and higher dropouts may cap stock upside, per Wells Fargo.
Already have an account? Sign in.